David B Darr
Overview
Explore the profile of David B Darr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1998
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tarpley M, Oladapo H, Strepay D, Caligan T, Chdid L, Shehata H, et al.
Eur J Pharm Sci
. 2021 Mar;
162:105821.
PMID: 33781856
DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase 1a) is highly expressed in glioma, an aggressive brain tumor, and has been proposed as a therapeutic target for cancer. In the current study, we...
2.
Sigmon J, Blanchard M, Baric R, Bell T, Brennan J, Brockmann G, et al.
Genetics
. 2020 Oct;
216(4):905-930.
PMID: 33067325
The laboratory mouse is the most widely used animal model for biomedical research, due in part to its well-annotated genome, wealth of genetic resources, and the ability to precisely manipulate...
3.
Bhatt A, Pellock S, Biernat K, Walton W, Wallace B, Creekmore B, et al.
Proc Natl Acad Sci U S A
. 2020 Mar;
117(13):7374-7381.
PMID: 32170007
Irinotecan treats a range of solid tumors, but its effectiveness is severely limited by gastrointestinal (GI) tract toxicity caused by gut bacterial β-glucuronidase (GUS) enzymes. Targeted bacterial GUS inhibitors have...
4.
Pfefferle A, Darr D, Calhoun B, Mott K, Rosen J, Perou C
Dis Model Mech
. 2019 Jun;
12(7).
PMID: 31213486
The Wnt gene family encodes an evolutionarily conserved group of proteins that regulate cell growth, differentiation and stem cell self-renewal. Aberrant Wnt signaling in human breast tumors has been proposed...
5.
Tanioka M, Mott K, Hollern D, Fan C, Darr D, Perou C
Genome Med
. 2018 Dec;
10(1):86.
PMID: 30497520
Background: Based on promising phase II data, the histone deacetylase inhibitor entinostat is in phase III trials for patients with metastatic estrogen receptor-positive breast cancer. Predictors of sensitivity and resistance,...
6.
Hollern D, Contreras C, Dance-Barnes S, Silva G, Pfefferle A, Xiong J, et al.
Breast Cancer Res Treat
. 2018 Nov;
174(1):143-155.
PMID: 30484104
Purpose And Methods: In human basal-like breast cancer, mutations and deletions in TP53 and BRCA1 are frequent oncogenic events. Thus, we interbred mice expressing the CRE-recombinase with mice harboring loxP...
7.
Cheng N, Watkins-Schulz R, Junkins R, David C, Johnson B, Montgomery S, et al.
JCI Insight
. 2018 Nov;
3(22).
PMID: 30429378
Triple-negative breast cancer (TNBC) has few therapeutic options, and alternative approaches are urgently needed. Stimulator of IFN genes (STING) is becoming an exciting target for therapeutic adjuvants. However, STING resides...
8.
Brighton H, Angus S, Bo T, Roques J, Tagliatela A, Darr D, et al.
Cancer Res
. 2017 Nov;
78(2):542-557.
PMID: 29180473
Targeted therapeutics that are initially effective in cancer patients nearly invariably engender resistance at some stage, an inherent challenge in the use of any molecular-targeted drug in cancer settings. In...
9.
Oladapo H, Tarpley M, Sauer S, Addo K, Ingram S, Strepay D, et al.
Cancer Lett
. 2017 Oct;
411:136-149.
PMID: 28965853
Activation of the Hedgehog (Hh) pathway effector GLI1 is linked to tumorigenesis and invasiveness in a number of cancers, with targeting of GLI1 by small molecule antagonists shown to be...
10.
Zawistowski J, Bevill S, Goulet D, Stuhlmiller T, Beltran A, Olivares-Quintero J, et al.
Cancer Discov
. 2017 Jan;
7(3):302-321.
PMID: 28108460
Targeting the dysregulated BRAF-MEK-ERK pathway in cancer has increasingly emerged in clinical trial design. Despite clinical responses in specific cancers using inhibitors targeting BRAF and MEK, resistance develops often involving...